HomeCompareALPN vs O

ALPN vs O: Dividend Comparison 2026

ALPN yields 3.08% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 O wins by $9.9K in total portfolio value· pulled ahead in Year 5
10 years
ALPN
ALPN
● Live price
3.08%
Share price
$64.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.4K
Annual income
$375.35
Full ALPN calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — ALPN vs O

📍 O pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALPNO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALPN + O cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALPN pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALPN
Annual income on $10K today (after 15% tax)
$261.66/yr
After 10yr DRIP, annual income (after tax)
$319.05/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, O beats the other by $4,014.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALPN + O for your $10,000?

ALPN: 50%O: 50%
100% O50/50100% ALPN
Portfolio after 10yr
$29.3K
Annual income
$2,736.77/yr
Blended yield
9.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

ALPN
Analyst Ratings
9
Buy
6
Hold
Consensus: Buy
Price Target
$55.00
-15.3% upside vs current
Range: $44.00 — $65.00
Altman Z
65.0
Piotroski
3/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.6% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALPN buys
0
O buys
0
No recent congressional trades found for ALPN or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALPNO
Forward yield3.08%5.28%
Annual dividend / share$2.00$3.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1%
Portfolio after 10y$24.4K$34.2K
Annual income after 10y$375.35$5,098.20
Total dividends collected$3.4K$20.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$55.00$64.00

Year-by-year: ALPN vs O ($10,000, DRIP)

YearALPN PortfolioALPN Income/yrO PortfolioO Income/yrGap
1$11,008$307.83$10,818$607.86+$190.00ALPN
2$12,095$316.69$11,786$741.30+$309.00ALPN
3$13,267$325.21$12,944$910.50+$323.00ALPN
4$14,529$333.38$14,343$1,127.28+$186.00ALPN
5← crossover$15,887$341.21$16,053$1,408.17$166.00O
6$17,348$348.70$18,167$1,776.65$819.00O
7$18,918$355.85$20,815$2,266.60$1.9KO
8$20,605$362.67$24,179$2,927.66$3.6KO
9$22,417$369.17$28,521$3,833.95$6.1KO
10$24,361$375.35$34,218$5,098.20$9.9KO

ALPN vs O: Complete Analysis 2026

ALPNStock

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Full ALPN Calculator →

OREIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this ALPN vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALPN vs SCHDALPN vs JEPIALPN vs KOALPN vs MAINALPN vs STAGALPN vs ADCALPN vs NNNALPN vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.